Advancing Therapeutic Delivery Through Trans-Oral Mucosal Technology InstaMed Pharmaceuticals
Tracy Gibbs, PhD InstaMed Chief Scientific Officer
Sarah Morgan, MS InstaMed Chief Executive Officer
Summary
InstaMed™ Pharmaceuticals is pioneering the future of active ingredient delivery for both Rx and Non Rx ingredients. Utilizing a patented ODS (Oral Dissolvable Strip) technology designed for trans-oral mucosal administration, including buccal and sublingual routes, we are providing a method for higher compliance and better user experience. Our technology utilizes the highly vascularized mucous membranes of the mouth to support bioavailability, bypass first-pass metabolism, and eliminate the need for injections or gastrointestinal absorption. Our oral dissolving strips are precision-engineered to adhere within the mouth, delivering a wide range of active ingredients directly into systemic circulation—quickly, effectively, and conveniently.
The Science of Trans-Oral Mucosal Delivery
Buccal and Sublingual Pathways
Trans-oral mucosal delivery exploits key regions in the mouth:
Buccal (cheek) mucosa
Sublingual (under the tongue) mucosa
Upper Palate (roof of mouth) mucosa
These routes allow active pharmaceutical ingredients (APIs) to diffuse through the mucosal epithelium and enter the rich capillary networks underneath, leading directly to systemic circulation. Oral dissolvable strips bypasses hepatic first-pass metabolism and gastrointestinal degradation—critical advantages for sensitive molecules like peptides, hormones, and small molecules.
InstaMed’s InstaRelease™ Technology
Our oral strips are engineered to:
Adhere to the buccal or sublingual mucosa, ensuring prolonged contact for absorption.
Dissolve at an ideal rate depending on the compound and intended kinetics.
Stabilize molecules, such as peptides, through proprietary formulation processes that preserves activity.
Support penetration with the use of patent pending molecules that support delivery based on the chemical characteristics of the actives.
Key Advantages of InstaMed’s InstaRelease™ Delivery
Non-invasive alternative to injections and bypass of gastrointestinal tract
Improved bioavailability, especially for peptides, hormones, and other labile compounds
Rapid onset of action due to direct bloodstream entry
Precision dosing and support for compliance through patient-friendly formats
Flexible adhesion options (buccal, sublingual, upper palate) depending on API properties and user preferences
Use Cases and Applications
InstaMed’s buccal delivery platform supports a wide range of functional and therapeutic ingredients, including:
Peptides
Hormones
Neurotropic agents
Non-Drug or Nutraceutical ingredients
Sexual wellness compounds
Conclusion
InstaMed’s patented trans-oral mucosal delivery system represents a breakthrough in therapeutic innovation. By merging scientific precision with user-friendly design, we are redefining how active compounds are absorbed and experienced—unlocking new opportunities for clinicians, brands, and patients alike.
Feb 15th 2014 Tracy Gibbs, PhD InstaMed Chief Scientific Officer and Sarah Morgan, MS InstaMed Chief Executive Officer